Intracellular BAPTA directly inhibits PFKFB3, thereby impeding mTORC1-driven Mcl-1 translation and killing

Flore Sneyers1, Martijn Kerkhofs1, Femke Speelman-Rooms1,2

  • 1KU Leuven, Laboratory of Molecular and Cellular Signaling, Department of Cellular and Molecular Medicine, Campus Gasthuisberg O&N I, Herestraat 49 box 802, 3000, Leuven, Belgium.

Cell Death & Disease
|September 8, 2023
PubMed

Insights

Intracellular BAPTA (BAPTAi) triggers apoptosis in MCL-1-dependent cancers by inhibiting glycolysis via PFKFB3, independent of Ca2+ signaling. This reveals PFKFB3 as a potential therapeutic target in these cancers.

Area of Science:

  • Cellular Biology
  • Cancer Research
  • Biochemistry

Background:

  • Intracellular calcium (Ca2+) signals regulate vital cellular functions.
  • Intracellular BAPTA (BAPTAi) chelates Ca2+ and was previously shown to enhance venetoclax-induced apoptosis in DLBCL.
  • This suggested an interplay between Ca2+ signaling and anti-apoptotic BCL-2 family proteins.

Purpose of the Study:

  • To elucidate the mechanisms by which BAPTAi enhances cell death in B-cell malignancies.
  • To investigate the role of intracellular Ca2+ signaling in BAPTAi-mediated effects.

Main Methods:

  • Investigated BAPTAi effects on hematological cancer cell lines, including BAX/BAK-deficient cells.
  • Assessed MCL-1 protein levels, mTORC1 activity, and glycolysis.
  • Examined the impact of BAPTAi and a low-affinity analog on PFKFB3 activity.

Main Results:

  • BAPTAi induced apoptosis in MCL-1-dependent hematological cancer cells by reducing MCL-1 protein levels.
  • This reduction was achieved by inhibiting mTORC1-driven Mcl-1 translation, independent of cell death.
  • BAPTAi impaired glycolysis by directly inhibiting 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) activity, a Ca2+-independent effect.

Conclusions:

  • BAPTAi inhibits PFKFB3, leading to impaired cellular metabolism and apoptosis in MCL-1-dependent cancer cells.
  • PFKFB3 inhibition represents a Ca2+-independent mechanism and a potential therapeutic target in these cancers.
  • The cellular effects of BAPTAi are not solely attributable to Ca2+ chelation, necessitating a re-evaluation of Ca2+'s role in studies using BAPTAi.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K